Aortic Valve Insufficiency

SAN FRANCISCO — Transcatheter aortic valve replacement with the self-expanding Acurate neo device did not meet noninferiority compared with the balloon-expandable Sapien 3 device for the primary composite safety and efficacy endpoint at 30 days, according to results of the SCOPE I trial.

PARIS — Patients with aortic stenosis have poor survival rates if their condition is left untreated, regardless of whether their stenosis is moderate or severe, researchers reported at the European Society of Cardiology Congress.

Edwards Lifesciences and Medtronic announced that their transcatheter aortic valve replacement systems have been approved by the FDA for use in patients with severe symptomatic aortic stenosis at low surgical risk.